VP
venBio Partners
Private EquityActivevenBio is a life sciences investment firm that partners with industry leaders to build game-changing medicines and technologies.
48
Investments
19
Exits
$386M
AUM
39.6%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for venBio Partners.
Investment Thesis & Strategy
venBio Partners is a life sciences-focused private equity firm that invests in various stages of companies developing innovative medicines and technologies. They partner with industry leaders to build impactful companies.
Investment Activity
Deals per year over the last 5 years
4
20173
20181
20190
20204
2021Portfolio Companies
Selected investments from their portfolio of 48 companies
N
NextPoint Therapeutics
Biotech · Series A, 2021
V
Ventyx Biosciences
Biotech · Series A, 2021
R
Rgenta Therapeutics
Biotech · Series A, 2021
K
Kyverna Therapeutics
Biotech · Series A, 2021
L
Lyell Immunopharma
Biotech · Series B, 2019
V
Vaxcyte
Biotech · Series A, 2018
T
Tessera Therapeutics
Biotech · Series A, 2018
S
Sana Biotechnology
Biotech · Series A, 2018
G
Gossamer Bio
Biotech · Series A, 2017
O
Obsidian Therapeutics
Biotech · Series A, 2017
T
Turning Point Therapeutics
Biotech · Series A, 2017
C
Cabaletta Bio
Biotech · Series A, 2017
Frequently Asked Questions
venBio Partners focuses on Series B, Series C+ stage investments.
Related Investors
Spectrum Equity
San Francisco, United States · 107 deals
Burrill & Company
San Francisco, United States · 87 deals
Foresite Capital
San Francisco, United States · 87 deals
FTV Capital
San Francisco, United States · 78 deals
Francisco Partners
San Francisco, United States · 49 deals
Serent Capital
San Francisco, United States · 36 deals